CAMBRIDGE, Mass., Sept. 17 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced the addition of two new executives. Claire Thom, Pharm.D., is the Senior Vice President, Portfolio Management and Isabelle Mercier joins Millennium as Vice President, Marketing for the Company’s Commercial organization.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080827/NEW076LOGO )
“We are very excited to have these two, highly-successful pharmaceutical executives join the Millennium team to help lead the organization towards becoming a top three global oncology company,” said Deborah Dunsire, M.D., President and CEO, Millennium. “Claire and Isabelle will offer insight and perspective to effectively develop and market the molecules in our expanding oncology pipeline as well as bring a proven level of entrepreneurship and innovative thinking.”
Claire Thom, Senior Vice President, Portfolio Management joins Millennium with nearly 20 years of experience in drug development, new product planning and marketing. In this role, she will be responsible for the oncology portfolio management process. Previously, Claire was responsible for the oversight and implementation of the global therapeutic area strategies for oncology, urology and gynecology franchises of Takeda Pharmaceutical Company in Japan. She also held several senior research and development as well as product planning positions at Takeda Global Research & Development and Takeda Pharmaceuticals North America. Prior to Takeda, Claire held positions of increasing responsibility at G.D. Searle and Company in the areas of global new product planning and US oncology marketing. She earned a Bachelor of Pharmacy degree with high honors and a Doctorate of Pharmacy with honors from the University of Illinois, Chicago.
Isabelle Mercier brings more than 16 years of global pharmaceutical marketing experience. As Vice President of Marketing, she will lead and develop US and global marketing strategy for the commercialization of late phase development products as well as oncology marketed products, including VELCADE(R) (bortezomib) for Injection for patients with multiple myeloma. Isabelle joins Millennium from sanofi-aventis and most recently served as Vice President of Taxotere Marketing. Additionally, she has US and global experience in sales, clinical research and oncology product launches from Sanofi-Synthelab and SangStat Medical Corporation. Isabelle earned dual Bachelor of Science degrees in Biochemistry and Clinical Biology from Universites Catholiques in Lyon, France as well as a Bachelor of Science degree in Genetic & Cellular Biology from l’Universite Lyon I in Lyon, France and an advanced degree in Biotechnologies from Universites Catholiques.
About Millennium
Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, www.millennium.com.
CONTACT: Karen Gobler of Millennium: The Takeda Oncology Company,
+1-617-444-1392, karen.gobler@mpi.com
Web site: http://www.millennium.com//
Company News On-Call: http://www.prnewswire.com/comp/114562.html /
